Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Want to see XERS full AI Analyst Report?
XERS Stock Chart & Stats
$6.37
<$0.01(0.15%)
At close: 4:00 PM EST
$6.37
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$4.40 - $10.08
Previous CloseN/A
Volume530.95K
Average Volume (3M)1.80M
Market Cap
$1.33B
Enterprise Value$1.12B
Total Cash (Recent Filing)$111.75M
Total Debt (Recent Filing)$37.33M
Price to Earnings (P/E)108.6
Beta1.29
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding172,642,060
10 Day Avg. Volume1,804,502
30 Day Avg. Volume1,797,482
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda24.21
Forecast
1Y Price Target
$12.33Price Target Upside93.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)$385.85M
Bulls Say, Bears Say
Bulls Say
Commercial DiversificationAnalyst cites commercial momentum across the product portfolio, with multiple products showing revenue growth and an expanding patient base that could diversify revenue sources.
Profitability And MarginsAnalyst expects expanding gross margins, improving operating leverage, and a self-sustaining balance sheet to support profitability while the company funds commercial expansion and pipeline development.
ValuationAnalyst notes the stock trades at a valuation discount to peers despite consistent commercial execution, implying potential for a market re-rating as investor focus shifts to fundamentals.
Bears Say
Growth Sustainability And Regulatory RiskAnalyst raises concern about whether the main drug's growth drivers can be sustained and warns that regulatory setbacks for a related product could undermine long-term revenue forecasts.
Visibility And VolatilityAnalyst highlights limited visibility into prescription trends between reporting periods, creating stock volatility and making interim company updates especially influential on valuation.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $4.40 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.33B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.003 by $0.013.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.01.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 172,642,060 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.003. Following the earnings report the stock price went up 4.082%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (93.62% Upside)
$12.33 (93.62% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.23%
12-Months-Change
Fundamentals
Return on Equity
735.00%
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution: substantial top-line growth (38% total revenue, 43% net product revenue), a near-doubling of Recorlev revenue (95% YoY), improved margins and profitability, and on-track pipeline progress with XP-8121 Phase III planned. Near-term headwinds were limited mainly to Gvoke (flat revenue) due to Medicare resets and increased near-term operating spend tied to deliberate commercial and R&D investments. Overall, positives (robust revenue growth, margin expansion, profitability, guidance raise and pipeline advancement) outweigh the operational and timing headwinds.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$12.33
▲(93.62% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
5.47% Insiders
11.08% Mutual Funds
13.21% Other Institutional Investors
58.26% Public Companies and
Individual Investors